期刊名称：PHARMACOGENETICS AND GENOMICS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Pharmacogenetics and Genomics is devoted to the rapid publication of research papers, brief review articles and short communications on genetic determinants in response to drugs and other chemicals in humans and animals. The Journal brings together papers from the entire spectrum of biomedical research and science, including biochemistry, bioinformatics, clinical pharmacology, clinical pharmacy, epidemiology, genetics, genomics, molecular biology, pharmacology, pharmaceutical sciences, and toxicology. Under a single cover, the Journal provides a forum for all aspects of the genetics and genomics of host response to exogenous chemicals: from the gene to the clinic.
Instructions to Authors
Guidance for Authors on the Preparation and Submission of Manuscripts to Pharmacogenetics and Genomics
Note: These instructions comply with those formulated by the International Committee of Medical Journal Editors. For further details, authors should consult the following article: International Committee of Medical Journal Editors. "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" N Engl J Med 1997;336:309-315. The complete document appears at http://www.icmje.org. Full details concerning many of the points below, including standard forms, are provided in the guidelines on the journal’s web site (http://www.pharmacogeneticsandgenomics.com/).
Editorial policy
The recipient editor will read each manuscript to determine whether it is appropriate for external peer review. Those deemed suitable will undergo external review; others will be rapidly returned to the corresponding author. Authors need not suggest referees, but the editors will respect the wishes of the corresponding author that the manuscript not be sent to a particular competing laboratory for review. Manuscripts will be judged solely on the basis of their content of original data and on the conclusions drawn from them. Manuscripts that report screening of mutant/variant allelic frequencies in an isolated population will no longer be considered for publication in Pharmacogenetics and Genomics, unless the mutant/variant is analysed with respect to an association with a particular disease or, in the special case, where comparisons of different populations add new insight into important clinical issues. In case-control studies, it is imperative that the allele(s) being analysed is (are) associated with a functional difference in expression of the gene product and that the gene product can be mechanistically linked to the disease being investigated. For example, is the disease mediated by chemicals or drugs that are metabolised by the gene product?
Points to consider before submission
We have prepared a standard covering letter (available from the journal website) to accompany your submission. Whether you use this letter or your own wording, please think carefully about the following points and make the appropriate declarations. Redundant or duplicate publication We ask you to confirm that your paper has not been published in its current form or a substantially similar form (in print or electronically, including on a web site), that it has not been accepted for publication elsewhere, and that it is not under consideration by another publication. The International Committee of Medical Journal Editors has provided details of what is and what is not duplicate or redundant publication (http://www.icmje.org). If you are in doubt (particularly in the case of material that you have posted on a web site), we ask you to proceed with your submission but to include a copy of the relevant previously published work or work under consideration by other journals. In your covering letter to the editors, draw attention to any published work that concerns the same patients or subjects as the present paper.
Conflicts of interest
We ask authors to state all possible conflicts of interest, including financial and other relationships. If you are sure that there is no conflict of interest, please state this. You might like to look at an editorial in the British Medical Journal on Beyond conflict of interest (http://bmj.com/cgi/content/short/317/7154/291). Remember that sources of funding should be acknowledged in your paper.
Permissions to reproduce previously published material
We ask you to send us copies of permission to reproduce material (such as illustrations) from the copyright holder. We cannot send your paper to press without these permissions.
Patient consent forms
The protection of a patient’s right to privacy is essential. We ask you to send copies of patient consent forms on which patients or other subjects of your experiments clearly grant permission for the publication of photographs or other material that might identify them. If the consent form for your research did not specifically include this, please obtain it or remove the identifying material. A sample patient consent form is available from the Journal’s website if required.
Ethics committee approval
You must state clearly in your submission in the Methods section that you conducted studies on human participants must with the approval of an appropriate named ethics committee. Please also look at the latest version of the Declaration of Helsinki (http://www.wma.net/e/policy/b3.htm). Similarly, you must confirm that experiments involving animals adhered to ethical standards and must state the care of animal and licensing guidelines under which the study was performed.
Authorship
We ask that all authors sign the submission letter. First, we have (rarely) had problems when someone named as an author was not aware of the submission of a paper and, on occasion, did not support the findings published. We therefore ask all authors to confirm that they have read and approved the paper. Second, we ask all authors to confirm that they have met the criteria for authorship as established by the International Committee of Medical Journal Editors, believe that the paper represents honest work, and are able to verify the validity of the results reported. We also ask that one person is named and agreed upon as the corresponding author who will act as the sole contact between the editors and publishers. Changes to submitted papers will only be accepted through the corresponding author, unless he/she submits in writing the authorization of an alternative contact. You might also be interested to read the debate on authorship in general in the British Medical Journal’s Authorship collection (http://bmj.com/cgi/collection/authorship).
Many of the points covered above are discussed in the New England Journal of Medicine’s collection of papers entitled ’Editorials on Journal Policy?(http://authors.nejm.org/Misc/Policies.asp).
Copyright assignment
Papers are accepted for publication on the understanding that exclusive copyright in the paper is assigned to the Publisher. Authors are asked to sign a copyright assignment form after acceptance of their papers. They may use material from their paper in other works published by them.
Submissions
Original articles, review and mini-review articles of 5000 words or less, editorials, invited commentaries on previously published material, together with rapid and short communications and scientific correspondence will all be included in Pharmacogenetics and Genomics. A mini-review discusses a focused topic of recent experimental research and makes it accessible to researchers both in the area of pharmacogenetics and genomics as well as in other related fields. A mini-review should provide a critical but balanced view of the field. It should direct the reader to not more than 40 key papers in the field. Personal communications and submitted manuscripts should not be cited. Mini-reviews are generally by invitation but proposals for mini-reviews may also be submitted to either the Chairman of the Editorial Board or the Editors. Material submitted or considered by the editors for rapid communication will be particularly time sensitive information and on acceptance will be accelerated through the publication process.
Authors are strongly encouraged to submit their manuscripts through the web-based tracking system at http://pgen.editorialmanager.com. Signed author forms may be included in the submission as a 'supporting document' or mailed to the journal office. The site contains instructions and advice on how to use the system. Authors should NOT in addition then post a hard copy submission to the editorial office, unless you are supplying artwork, letters or files that cannot be submitted electronically, or have been instructed to do so by the editorial office. Include the following where appropriate: subject consent forms; transfer of copyright form; permission to reproduce previously published material; checklist. For those authors who have no option but to submit by mail please send one copy of the article, plus an electronic version on disk or CD-ROM to one of the following editors: (a) Mark J. Ratain, M.D., Cancer Research Center, The University of Chicago, 5841 S. Maryland Ave., MC 2115
Chicago, IL 60637; Email: mratain@medicine.bsd.uchicago.edu (b) M. Eichelbaum, Dr Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Auerbachstr. 112, 70376 Stuttgart, Germany. Tel: +49 711 8101 3700; fax: +49 711 859 295; e-mail: michel.eichelbaum@ikp-stuttgart.de.
Double spacing should be used throughout the manuscript, which should include the following sections, each starting on a separate page: title page, abstract and keywords, text, acknowledgements, references, individual tables and captions. Margins should be not less than 3 cm. Pages should be numbered consecutively, beginning with the title page, and the page number should be placed in the top right hand corner of each page. Abbreviations should be defined on their first appearance in the text; those not accepted by international bodies should be avoided. Submit the required number of paper copies and keep copies of everything submitted.
Presentation of Papers
Title Page
The title page should carry the full title of the paper and a short title, of no more than 45 characters and spaces, to be used as a ‘running head?(and which should be so identified). The first name, middle initial and last name of each author should appear. If the work is to be attributed to a department or institution, its full name should be included. Any disclaimers should appear on the title page, as should the name and address of the author responsible for correspondence concerning the manuscript and the name and address of the author to whom requests for reprints should be made. Finally, the title page should include the sources of any support for the work in the form of grants, equipment, drugs, or any combination of these.
Abstracts
The second page should carry a structured abstract of no more than 250 words. The abstract should state the Objective(s) of the study or investigation, basic Methods (selection of study subjects or laboratory animals; observational and analytical methods), main Results (giving specific data and their statistical significance, if possible), and the principal Conclusions. It should emphasise new and important aspects of the study or observations. Short communications should include an unstructured summary of no more than 150 words.
Key Words
The abstract should be followed by a list of 3 - 10 keywords or short phrases which will assist the cross-indexing of the article and which may be published. When possible, the terms used should be from the Medical Subject Headings list of the Index Medicus (http://www.nlm.nih.gov/mesh/meshhome.html).
Text
Full papers of an experimental or observational nature may be divided into sections headed Introduction, Methods (including ethical and statistical information), Results and Discussion (including a conclusion), although invited commentaries and reviews may require a different format. Rapid Communications should comprise up to 1500 words, up to 15 references, and up to 2 inserts (2 figures, or 2 tables, or 1 figure and table). Short Communications should comprise a single item of text of no more than 1500 words and containing up to 10 references.
Acknowledgements
Acknowledgements should be made only to those who have made a substantial contribution to the study. Authors are responsible for obtaining written permission from people acknowledged by name in case readers infer their endorsement of data and conclusions.
References
References should be numbered consecutively in the order in which they first appear in the text. They should be assigned Arabic numerals, which should be given in brackets, e.g. [17]. References should include the names of all authors when six or fewer; when seven or more, list only the first six names and add et al. References should also include full title and source information. Journal names should be abbreviated as in the Index Medicus (http://www.nlm.nih.gov/tsd/serials/terms_cond.html).
Articles in journals
Standard journal article: Gelboin HV, Huberman E, Sach L. Enzymic hydroxylation of benzopyrene and its relationship to cytotoxicity. Proc Natl Acad Sci USA 1976; 64: 1188?194.
Books
Book: Armitage P, Berry G. Statistical methods in medical research. 2nd edition. Oxford: Blackwell Scientific Publications; 1987.
Chapter in a book: Nebert DW. Genes encoding drugmetabolizing enzymes: possible role in human disease. In: Woodhead AD, Bender M-A, Leonard RC, eds. Phenotypic variation in populations: Relevance to risk assessment. New York: Plenum Press; 1988. pp. 45?4.
Personal communications and unpublished work should not feature in the reference list but should appear in parentheses in the text. Unpublished work accepted for publication but not yet released should be included in the reference list with the words ‘in press?in parentheses beside the name of the journal concerned. References must be verified by the author(s) against the original documents.
Tables
Each table should be typed on a separate page in double spacing. Tables should not be submitted as photographs. Each table should be assigned an Arabic numeral, e.g. (Table 3) and a brief title. Vertical rules should not be used. Place explanatory matter in footnotes, not in the heading. Explain in footnotes all non-standard abbreviations that are used in each table. Identify statistical measures of variations, such as standard deviation and standard error of the mean.
Be sure that each table is cited in the text. If you use data from another published or unpublished source, obtain permission and acknowledge the source fully.
Illustrations
References to figures and tables should be made in order of appearance in the text and should be in Arabic numerals in parentheses, e.g. (Fig. 2). Most file formats are accepted, but TIFF and EPS files, with fonts embedded, are preferred. If scanned, line art should be at a resolution of 800 dpi, and halftones and colour at 300 dpi. All colour values should be CMYK. If hard copies are submitted they should have a label pasted to the back bearing the figure number, the title of the paper, the author’s name and a mark indicating the top of the figure. Illustrations should be presented to a width of 82 mm or, when the illustration demands it, to a width of 166 mm. Photomicrographs must have internal scale markers. If photographs of people are used, their identities must be obscured or the picture must be accompanied by written consent to use the photograph. If a figure has been published before, the original source must be acknowledged and written permission from the copyright holder for both print and electronic formats should be submitted with the material. Permission is required regardless of authorship or publisher, except for documents in the public domain. Figures may be reduced, cropped or deleted at the discretion of the editor. Colour illustrations are acceptable but authors will be expected to cover the extra reproduction costs (for current charges, contact the publisher).
Legends for illustrations
Captions should be typed in double spacing, beginning on a separate page. Each one should have an Arabic numeral corresponding to the illustration to which it refers. Internal scales should be explained and staining methods for photomicrographs should be identified.
Units of measurement
Measurements of length, height, weight, and volume should be reported in metric units (metre, kilogram, or litre) or their decimal multiples. Temperatures should be given in degrees Celsius. Blood pressures should be given in millimetres of mercury.
All haematologic and clinical chemistry measurements should be reported in the metric system in terms of the International System of Units (SI). Editors may request that alternative or non-SI units be added by the authors before publication.
Abbreviations and symbols
Use only standard abbreviations. Avoid abbreviations in the title and abstract. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement.
Nomenclature
Authors are asked to confirm in their covering letter of submission, that their manuscript complies with the nomenclature guidelines developed by the HUGO nomenclature committee for human genes. The guidelines can be found at the following sites:
Human genes
Use genetic notation and symbols approved by the HUGO Nomenclature Committee. Before submission, approved gene symbols should be obtained from the HUGO Nomenclature Committee (www.gene.ucl.ac.uk/nomenclature). Useful reference articles and forms: White et al. (1997), ’Guidelines for Human Gene Nomenclature? Genomics, 45, 468-471]; to submit new gene names, the Gene Name Proposal form may be completed on the nomenclature web page: (www.gene.ucl.ac.uk/nomenclature).
Human genetic variation
Designation of single nucleotide polymorphisms (SNPs), deletions, insertions and other gene mutations should follow the guidelines given in Hum Genet 2001; 109:121?24. The nomenclatures for allelic variations of human P450s should adhere to the recommendations given at http://www.imm.ki.se/CYPalleles/ those of N-acetyl transferases at http://www.louisville.edu/medschool/pharmacology/NAT.html and those of UDP glycosyltransferases in Pharmacogenetics 1997; 7:255?69.
Human cytogenics
Use ISCN nomenclature for cytogenetics notation [Mitelman, F. (ed.) ISCN 1995: An International System for Human Cytogenetic Nomenclature, S. Karger, Basel]. Human gene names and loci should be written in uppercase italics and Arabic numerals. Protein products are not italicised.
Mouse strain and genetic nomenclature
International Committee on Standardised Genetic Nomenclature for Mice (http://www.informatics.jax.org/) new symbols and names for genes should be obtained before submission (http://www.informatics.jax.org/).
Offprints
Offprints may be purchased using the appropriate form that will be made available with proofs. Orders should be sent when the proofs are returned; orders received after this time cannot be fulfilled.
Editorial Board
Editors
M. Eichelbaum
Dr Margarete Fischer-Bosch-Institut
f?r Klinische Pharmacologie
Auerbachstr 112
70376 Stuttgart
Germany
Tel: +49 711 8101 3700
Fax: +49 711 859 295
E-mail: michel.eichelbaum@ikp-stuttgart.de
W. E. Evans
St. Jude Children's Research Hospital
332 N. Lauderdale St.
Room D1052
Memphis, Tennessee 38105
USA
Tel: +1 901 495 3663
Fax: +1 901 525 6869
E-mail: william.evans@stjude.org
Emeritus Chairman of the Editorial Board
W. Kalow
Toronto, Canada
Chairman of the Board
M. Ingelman-Sundberg
Stockholm, Sweden
Editorial Board
R. B. Altman
Stanford, USA
H. Brauch
Stuttgart, Germany
J. Brockm?ller
Gottingen, Germany
F. Cambien
Paris, France
I. Cascorbi
Greifswald, Germany
J. Chang-Claude
Heidelberg, Germany
M. W. H. Coughtrie
Dundee, UK
K. M. Giacomini
San Francisco, CA, USA
F. J. Gonzalez
Bethesda, MD, USA
P. A. Insel
La Jolla, CA, USA
T. Ishizaki
Kumamoto, Japan
J. A. Johnson
Gainesville, FL, USA
T. Kamataki
Sapporo, Japan
L. S. Kaminsky
Albany, NY, USA R. Kato
Tokyo, Japan
D. Keppler
Heidelberg, Germany
R. Kerwin
London, UK
M. Krawczak
Kiel, Germany
E. Y. Krynetski
Memphis, TN, USA
S. B. Liggett
Cincinnati, OH, USA
H. J. Lin
Torrance, CA, USA
H. L. McLeod
St Louis, MO, USA
M. E. McManus
Queensland, Australia
P. J. Meier-Abt
Z?rich, Switzerland
U. A. Meyer
Basel, Switzerland
J. O. Miners
Adelaide, Australia
D. W. Nebert
Cincinnati, OH, USA
D. Nickerson
Seattle, WA, USA M. M. Nöthen
Antwerp, Belgium
K. Park
Liverpool, UK
P. Propping
Bonn, Germany
H. Raunio
Kuopio, Finland
M. V. Relling
Memphis, TN, USA
D. Roden
Nashville, TN, USA
D. Schrenk
Kaiserslautern, Germany
E. Schuetz
Memphis, TN, USA
A. Somogyi
Adelaide, Australia
A. Thithapandha
Bangkok, Thailand
K. Thummel
Seattle, WA, USA
P. B. Watkins
Ann Arbor, MI, USA
W. W. Weber
Ann Arbor, MI, USA
R. Weinshilboum
Rochester, MN, USA
|
